Back to results
US 12,016,883 B2Granted
Primary T-cell expansion
AssigneeNantBio, Inc.
InventorsKrsto Sbutega, Peter Sieling, Adam D. Lazar, Kayvan Niazi
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.
Claims9
A method of in-vitro primary T cell growth, comprising:
- enriching T cells in a blood sample;
- stimulating the T cells with an anti-CD2 antibody, an anti-CD3 antibody, and/or an anti-CD28 antibody;
- expanding the T cells in the presence of IL-2, IL-7, and IL-15 to at least 30-fold expansion,
- wherein the step of expansion comprises serial dilution of the T cells by increasing the culture volume by at least 2-fold at least once every 7 days,
- wherein the serial dilution is carried out in a single and continuous culture device having an inlet and exit of cell culture medium to permit adequate flow to growth surfaces;
- harvesting the expanded T cells;
- and
- cryopreserving the expanded T cells at a concentration of 10 million to 15 million cells per milliliter.
5 more elements
Dependencies are inferred from the claim text.